Business, energy, technology, markets and global industry news from Business News Today

ASCO 2026

PharmaDeviceNews ASCO 2026
Representative image of clinicians reviewing genomic cancer testing data and medical imaging, reflecting Veracyte’s Prosigna and Decipher ASCO 2026 results and the growing role of precision oncology diagnostics in breast cancer and prostate cancer treatment decisions.
Medical Devices & Diagnostics

Can Veracyte’s Prosigna data change chemotherapy decisions in high-risk breast cancer?

Veracyte’s ASCO data could reshape chemotherapy decisions in breast and prostate cancer. Find out why genomic testing is gaining ground.

Read More
Representative image of oncologists reviewing advanced gastric cancer imaging in a modern cancer care setting, reflecting Ono Pharmaceutical’s ONO-4578 Phase 2 data and the race to improve first-line treatment for HER2-negative gastric and gastroesophageal junction cancer.
Pharma & Biotech

Can Ono and Deciphera turn ONO-4578 into a global Phase 3 oncology contender?

Ono’s ONO-4578 improved gastric cancer PFS in Phase 2. The next test is whether EP4 blockade can survive global Phase 3 scrutiny.

Read More
Representative image of an oncologist reviewing head and neck cancer scans in a modern clinical setting, reflecting Fulgent Genetics’ FID-007 Phase 2 data and the growing search for new post-PD-1 treatment options in recurrent or metastatic head and neck cancer.
Pharma & Biotech

Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026

Fulgent Genetics has a diagnostics base and a cancer drug signal. FID-007 now faces the tougher Phase 3 test.

Read More
Pharma & Biotech

Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens

Minghui and Qilu’s MHB088C data show durable disease control in mCRPC. Find out why the B7-H3 ADC still faces key clinical tests.

Read More
Representative image of liver cancer research and CAR-T therapy development, reflecting growing industry interest in Oricell’s Ori-C101 data for late-line hepatocellular carcinoma.
Pharma & Biotech

Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight

Find out how Oricell’s Ori-C101 CAR-T data could reshape expectations for late-line liver cancer treatment after ASCO 2026.

Read More
Representative image: A clinician reviews lung cancer imaging as ivonescimab survival data from the HARMONi-6 study raise fresh questions about the future of first-line squamous non-small cell lung cancer treatment.
Pharma & Biotech

Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?

Ivonescimab showed an overall survival benefit in HARMONi-6. Read how the data could reshape first-line squamous NSCLC treatment.

Read More
Representative image of an oncology researcher reviewing colorectal cancer scan data, reflecting Pfizer’s Braftovi regimen update in BRAF V600E-mutant metastatic colorectal cancer.
Pharma & Biotech

Is Pfizer’s Braftovi regimen becoming the new benchmark for BRAF-mutant colorectal cancer?

Pfizer’s Braftovi data strengthen its role in BRAF V600E metastatic colorectal cancer. Find out what this could change next.

Read More
Representative image of oncology researchers analysing cancer imaging and laboratory data as SalubrisBio’s JK06 antibody drug conjugate shows early Phase 1/2 promise in 5T4-targeted treatment for lung cancer and breast cancer.
Pharma & Biotech

SalubrisBio’s JK06 shows early promise, but can 5T4 ADCs move beyond niche excitement?

Find out how SalubrisBio’s JK06 data could reshape 5T4-targeted ADC development in lung and breast cancer.

Read More
Representative image of an oncology consultation for advanced prostate cancer treatment, as Bayer’s NUBEQA cognitive decline data from the ARACOG trial raises new questions about quality-of-life differences between darolutamide and enzalutamide.
Pharma & Biotech

Could Bayer’s NUBEQA gain a quality-of-life edge after ARACOG cognitive data?

Find out how Bayer’s NUBEQA cognitive data from ARACOG could reshape prostate cancer treatment choices after ASCO 2026.

Read More
Medical Devices & Diagnostics

Can Veracyte’s Decipher Prostate test change who gets chemotherapy in metastatic prostate cancer?

Can Veracyte’s Decipher Prostate test change chemotherapy decisions in metastatic prostate cancer? Find out what ENZAMET data means today.

Read More